Tocilizumab as a Potential Adjunctive Therapy to Corticosteroids in Cryptococcal Post-infectious Inflammatory Response Syndrome (PIIRS): a Report of Two Cases.

Abstract

PURPOSE:

Non-HIV cryptococcal meningoencephalitis (CM) in previously healthy individuals is often complicated by a post-infectious inflammatory response syndrome (c-PIIRS) characterized by neurologic deterioration after appropriate antifungal therapy with sterilization of CSF fungal cultures. c-PIIRS results from an excessive inflammatory response to fungal antigens released during fungal lysis, mediated by IFN-γ, IL-6, and activated T-helper cells, leading to immune-mediated host damage that responds to pulse-corticosteroid taper therapy (PCT). Typically, oral steroids may take up to a year to taper, and occasionally, patients will be refractory to steroid therapy or may demonstrate high-risk lesions such as those involving intracranial arteries. Also, patients can have problematic side effects from prolonged corticosteroids. Hence, appropriate adjunctive agents are needed to reduce corticosteroid doses in the treatment of c-PIIRS. Due to a possible role of IL-6 in pathogenesis, IL-6 receptor blockade by tocilizumab may be useful in the treatment of c-PIIRS.

METHODS:

Two previously healthy patients with non-HIV cPIIRS were seen at the NIH. Due to concerns for intracranial vascular rupture in an area of inflammation (Patient 1) and intractable symptoms on high-dose oral corticosteroids (Patient 2) with evidence of persistent CSF inflammation, patients were treated with 4-8 mg/kg tocilizumab every 2 weeks while maintained on a constant dose of prednisone.

RESULTS:

Two patients exhibited rapid immunological improvement following treatment with tocilizumab. Patient 1 remained vascularly stable, and Patient 2 had near resolution of headaches with improvement in mental status as evidenced by improved MOCA score. The two had improved CSF inflammatory parameters and no significant side effects. Both CSF cultures remained negative throughout treatment.

CONCLUSIONS:

Tocilizumab may be a safe adjunctive treatment for CM-related PIIRS suggesting further study.

• Authors: Jessica C Hargarten, Seher H Anjum, Kenneth Ssebambulidde, Yoon-Dong Park, Malcolm J Vaughan, Terri L Scott, Dima A Hammoud, Bridgette Jeanne Billioux, Peter R Williamson
• Journal: Journal of clinical immunology (J Clin Immunol) Vol. 43 Issue 8 Pg. 2146-2155 (Nov 2023) ISSN: 1573-2592 [Electronic] Netherlands
• PMID: 37814084 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Chemical References

• tocilizumab
• Interleukin-6
• Adrenal Cortex Hormones

Topics

• Humans
• Meningitis, Cryptococcal (diagnosis, drug therapy)
• Interleukin-6
• Cryptococcus
• Inflammation
• Adrenal Cortex Hormones (therapeutic use)
• Meningoencephalitis (drug therapy)